December 31, 2010
2010
- ReadCapri S, Benucci M, Iannazzo S, Zaniolo O, D’Arpino A. Un modello di Budget Impact per la valutazione economica di tocilizumab come prima linea biologica nei pazienti con artrite reumatoide di grado moderato o severo. Italian Journal of Public Health – Year 8, Volume 7, Number 2, Suppl 2, 2010: S44-53
- ReadEandi M, Pradelli L, Iannazzo S, Chiroli S, Pontoriero G. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010; 28(11): 1041-54
- ReadBenucci M, Iannazzo S, Zaniolo O, Sabadini L. Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis. Clin Exp Rheumatol 2010; 28(5): 722-7
- ReadPradelli L, Iannazzo S, Zaniolo O, Botrugno P. Organization and Estimated Patient-Borne Costs of Oral Anticoagulation Therapy in Italy: Results from a Survey. Appl Health Econ Health Policy 2010; 8 (2): 119-128
- ReadZaniolo O, Wolowacz SE, Pradelli L. Cost/effectiveness model of dabigatran in the prevention of venous thromboembolism in major orthopedic surgery: Adaptation for Italy. Farmeconomia e percorsi terapeutici 2010; 11(2): 91-101
- ReadSacchi V, Zaniolo O, Olivieri I. Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept. Farmeconomia e percorsi terapeutici 2010; 11(2): 63-76
- ReadZaniolo O, Sacchi V, Dal Negro RW. Tiotropium in COPD: clinical outcomes and economic evidence. Farmeconomia e percorsi terapeutici 2010; 11(1): 27-41
No Comments
Sorry, the comment form is closed at this time.